ReShape Lifesciences Inc.

NASDAQ: RSLS · Real-Time Price · USD
3.92
0.72 (22.50%)
At close: Aug 14, 2025, 3:59 PM

ReShape Lifesciences Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
693K 4.46M 3.85M 22.77M
Short-Term Investments
n/a n/a n/a n/a
Long-Term Investments
n/a n/a n/a -555K
Other Long-Term Assets
29K 29K 46K 1.46M
Receivables
987K 1.66M 2.18M 2.81M
Inventory
2.46M 3.74M 3.61M 3M
Other Current Assets
114K 239K 184K 238K
Total Current Assets
4.59M 10.3M 9.91M 30.25M
Property-Plant & Equipment
154K 310K 869K 1.72M
Goodwill & Intangibles
n/a n/a 260K 20.83M
Total Long-Term Assets
205K 367K 1.23M 24M
Total Assets
4.79M 10.66M 11.14M 54.26M
Account Payables
2.21M 1.69M 1.93M 3.47M
Deferred Revenue
n/a 44K 510K 549K
Short-Term Debt
811K n/a 171K 279K
Other Current Liabilities
1.82M 1.17M 3.38M 1.98M
Total Current Liabilities
4.99M 3.78M 7.48M 7.33M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
61K 72K -123K 855K
Total Long-Term Liabilities
61K 223K 2.61M 855K
Total Liabilities
5.05M 4M 7.48M 8.19M
Total Debt
967K 262K 171K 279K
Common Stock
n/a 23K 1K 18K
Retained Earnings
-642.7M -635.57M -624.19M -576.76M
Comprehensive Income
-104K -88K -88K -92K
Shareholders Equity
-253K 6.66M 3.66M 46.07M
Total Investments
n/a n/a n/a -555K